ESMO 2017 | Pembrolizumab demonstrates promise in patients with pretreated metastatic gastric cancer

Zev Wainberg

Zev A. Wainberg, MD from the University of California Medical Centre, CA, USA summarises the results of the KEYNOTE-059 Update study in patients with pre-treated metastatic gastric cancer. Presented at the ESMO 2017 Congress in Madrid, Spain, Pembrolizumab has shown a promising response rate. The expected survival of patients with metastatic gastric cancer is less than one year and very few new drugs have been approved for this disease in the past decade. The phase II KEYNOTE-059 is one of the largest studies to investigate immunotherapy in recurrent or metastatic gastric cancer and is an important study for gastric cancer, where new treatments are desperately needed. Watch the video to find out more. Recorded during the ESMO 2017 Congress.

Share this video